Digistain
Digistain is a UK-based company that has developed a transformational breast cancer biomarker analytics technology. Their Digistain Test is an MHRA-cleared, UKCA-marked solution that assesses the risk of recurrence in breast cancer patients after surgery. It provides a 10-year risk score, guiding clinicians on adjuvant chemotherapy decisions. Unlike traditional methods that are slow and expensive, Digistain offers a rapid, AI-enabled solution delivering results in under an hour at a fraction of the cost. It is designed for Stage I-II, HER2-, ER+ breast cancer patients with up to 3 positive lymph nodes. The company was founded by Dr. Hemmel Amrania, who patented a novel method for grading tumor biopsies. Digistain aims to eliminate inequalities in breast cancer care by making accurate, timely, and affordable predictive tests accessible.
Digistain
Digistain is a UK-based company that has developed a transformational breast cancer biomarker analytics technology. Their Digistain Test is an MHRA-cleared, UKCA-marked solution that assesses the risk of recurrence in breast cancer patients after surgery. It provides a 10-year risk score, guiding clinicians on adjuvant chemotherapy decisions. Unlike traditional methods that are slow and expensive, Digistain offers a rapid, AI-enabled solution delivering results in under an hour at a fraction of the cost. It is designed for Stage I-II, HER2-, ER+ breast cancer patients with up to 3 positive lymph nodes. The company was founded by Dr. Hemmel Amrania, who patented a novel method for grading tumor biopsies. Digistain aims to eliminate inequalities in breast cancer care by making accurate, timely, and affordable predictive tests accessible.